Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
The 78th World Health Assembly has been a whirlwind week for ADI as, after 18-months of advocacy, the World Health Assembly has agreed to extend the Global Action Plan on the Public Health Response to Dementia by 6-years, to 2031.
Lecanemab is the first therapy of its kind approved in the EU that could potentially slow the progression of Alzheimer’s disease. The use of lecanemab will now be considered by national payers, who will assess the treatment against further nationally determined criteria.
The annual Alzheimer University (AU) assists emerging Alzheimer and dementia associations.
World Alzheimers Month 2021 has just ended and marks the most successful awareness raising campaign to date in its decade long history.
Eisai’s lecanemab will represent the second anti-Amyloid Beta therapy to be evaluated by the FDA as a disease modifying treatment for early Alzheimer’s disease.
This is the press release for the World Alzheimer Report 2021 'Journey through the diagnosis of dementia'
This report reviews progress towards the implementation of the 7 action areas of the plan by Member States, WHO and civil society, and all those involved in tackling the dementia pandemic.
People living with dementia and carers from all over the world have shared their experience of the journey to diagnosis for this year's World Alzheimer's Month campaign.
World Alzheimer’s Month is just around the corner and the STRiDE (Strengthening responses to dementia in developing countries) project teams have been busy planning activities to raise awareness and keep dementia on the policy agenda. The STRiDE project is led by the London School of Economics and Political Science, in…
Learn how you can support World Alzheimer's Month virtually this September.